参 考 文 献
［1] MEHTA S R，WOOD D A，STOREY R F，et al. Complete revascularization with multivessel PCI for myocardial infarction ［J］.N Engl J Med，2019，381（15）：1411-1421.
［2] LEMKES J S，JANSSENS G N，VAN DER HOEVEN N W，et al. Coronary angiography after cardiac arrest without ST-segment elevation ［J］. N Engl J Med，2019，380（15）：1397-1407.
［3] HOCHMAN J S. International Study Of Comparative Health Effectiveness With Medical And Invasive Approaches（ISCHEMIA）：primary report of clinical outcomes. American Heart Association Scientific Sessions 2019［G］. Philadelphia，2019：16-18.
［4] FARKOUH M E，DOMANSKI M，DANGAS G D，et al. Long-term survival following multivessel revascularization in patients with diabetes：The FREEDOM follow-on study ［J］. J Am Coll Cardiol，2019，73（6）：629-638.
［5] THUIJS D，KAPPETEIN A P，SERRUYS P W，et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease：10-year follow-up of the multicentre randomised controlled SYNTAX trial ［J］. Lancet，2019，394（10206）：1325-1334.
［6] STONE G W，KAPPETEIN A P，SABIK J F，et al. Five-year outcomes after PCI or CABG for left main coronary disease ［J］.N Engl J Med，2019，381（19）：1820-1830.
［7] HOLM N R，MAKIKALLIO T，LINDSAY M M，et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis：updated 5-year outcomes from the randomised，non-inferiority NOBLE trial［J］. Lancet，2020，395（10219）：191-199.
［8] PARK D W，AHN J M，PARK H，et al. Ten-year outcomes after drug-eluting stents versus coronary artery bypass grafting for left main coronary disease：Extended follow-up of the PRECOMBAT trial ［J］. Circulation，2020，141（18）：1437-1446.
［9] CHEN X，LI X，ZHANG J J，et al. 3-year outcomes of the DKCRUSH-Ⅴ trial comparing DK crush with provisional stenting for left main bifurcation lesions ［J］. JACC Cardiovasc Interv，2019，12（19）：1927-1937.
［10] LEE S W，LEE P H，AHN J M，et al. Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion ［J］. Circulation，2019，139（14）：1674-1683.
［11] BUITEN R A，PLOUMEN E H，ZOCCA P，et al. Outcomes in patients treated with thin-strut，very thin-strut，or ultrathinstrut drug-eluting stents in small coronary vessels：A prespecified analysis of the randomized BIO-RESORT trial ［J］. JAMA Cardiol，2019，4（7）：659-669.
［12] GIACOPPO D，ALFONSO F，XU B，et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis：a comprehensive，collaborative，individual patient data meta-analysis of 10 randomized clinical trials（DAEDALUS study）［J］. Eur Heart J，2019：ehz594. ［Online ahead of print］
［13] GIACOPPO D，ALFONSO F，XU B，et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis ［J］. J Am Coll Cardiol，2020，75（21）：2664-2678.
［14] BRINTON T J，ALI Z A，HILL J M，et al. Feasibility of shockwave coronary intravascular lithotripsy for the treatment of calcified coronary stenoses ［J］. Circulation，2019，139（6）：834-836.
［15] ALI Z A，NEF H，ESCANED J，et al. Safety and effectiveness of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses：The disrupt CAD Ⅱ study ［J］. Circ Cardiovasc Interv，2019，12（10）：e008434.
［16] IGLESIAS J F，MULLER O，HEG D，et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction（BIOSTEMI）：a single-blind，prospective，randomised superiority trial ［J］. Lancet，2019，394（10205）：1243-1253.
［17] RISSANEN T T，USKELA S，ERANEN J，et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk（DEBUT）：a single-blind，randomised，non-inferiority trial ［J］. Lancet，2019，394（10194）：230-239.
［18] MEHRAN R，BABER U，SHARMA S K，et al. Ticagrelor with or without aspirin in high-risk patients after PCI ［J］. N Engl J Med，2019，381（21）：2032-2042.
［19] LOPES R D，HEIZER G，ARONSON R，et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation ［J］. N Engl J Med，2019，380（16）：1509-1524.
［20] ALEXANDER J H，WOJDYLA D，VORA A N，et al. Risk/Benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention：Insights from AUGUSTUS［J］. Circulation，2020，141（20）：1618-1627.